Vanessa Selak

Summary

Affiliation: University of Auckland
Country: New Zealand

Publications

  1. ncbi request reprint Smoking status recording in GP electronic records: the unrealised potential
    Vanessa Selak
    Clinical Trials Research Unit, The University of Auckland, New Zealand
    Inform Prim Care 14:235-41; discussion 242-5. 2006
  2. doi request reprint IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care
    Vanessa Selak
    Clinical Trials Research Unit, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    Contemp Clin Trials 32:909-15. 2011
  3. ncbi request reprint Aspirin for primary prevention: yes or no?
    Vanessa Selak
    Clinical Trials Research Unit, School of Population Health, The University of Auckland, Auckland, New Zealand
    J Prim Health Care 2:92-9. 2010
  4. doi request reprint Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice
    Sue Wells
    School of Population Health, University of Auckland, Auckland, New Zealand
    Eur J Cardiovasc Prev Rehabil 15:173-8. 2008
  5. doi request reprint Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care
    Vanessa Selak
    National Institute for Health Innovation, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    BMJ 348:g3318. 2014
  6. pmc Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial
    Vanessa Selak
    National Institute of Health Innovation, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    Int J Equity Health 12:44. 2013
  7. ncbi request reprint Gaps in primary care documentation of cardiovascular risk factors
    Natasha Rafter
    Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
    N Z Med J 121:24-33. 2008
  8. doi request reprint Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial
    Vanessa Selak
    Department of Epidemiology and Biostatistics, University of Auckland, New Zealand
    Eur J Prev Cardiol 23:1537-45. 2016
  9. pmc The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials
    C Raina Elley
    School of Population Health, University of Auckland, Auckland, New Zealand
    PLoS ONE 7:e52145. 2012
  10. ncbi request reprint Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand
    C Raina Elley
    Department of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand
    Diabetes Res Clin Pract 79:468-73. 2008

Detail Information

Publications13

  1. ncbi request reprint Smoking status recording in GP electronic records: the unrealised potential
    Vanessa Selak
    Clinical Trials Research Unit, The University of Auckland, New Zealand
    Inform Prim Care 14:235-41; discussion 242-5. 2006
    ....
  2. doi request reprint IMProving Adherence using Combination Therapy (IMPACT): design and protocol of a randomised controlled trial in primary care
    Vanessa Selak
    Clinical Trials Research Unit, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    Contemp Clin Trials 32:909-15. 2011
    ..However, prescribing and adherence rates are low and CVD events remain high...
  3. ncbi request reprint Aspirin for primary prevention: yes or no?
    Vanessa Selak
    Clinical Trials Research Unit, School of Population Health, The University of Auckland, Auckland, New Zealand
    J Prim Health Care 2:92-9. 2010
    ....
  4. doi request reprint Integrated electronic decision support increases cardiovascular disease risk assessment four fold in routine primary care practice
    Sue Wells
    School of Population Health, University of Auckland, Auckland, New Zealand
    Eur J Cardiovasc Prev Rehabil 15:173-8. 2008
    ..A web-based decision support system (PREDICT-CVD), integrated with primary care electronic medical record software was developed as one strategy to address this problem...
  5. doi request reprint Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care
    Vanessa Selak
    National Institute for Health Innovation, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    BMJ 348:g3318. 2014
    ..To evaluate whether provision of fixed dose combination treatment improves adherence and risk factor control compared with usual care of patients at high risk of cardiovascular disease in primary care...
  6. pmc Recruiting equal numbers of indigenous and non-indigenous participants to a 'polypill' randomized trial
    Vanessa Selak
    National Institute of Health Innovation, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    Int J Equity Health 12:44. 2013
    ..Therefore, the IMPACT trial aimed to recruit as many Māori as non-Māori to assess the consistency of the effect of the polypill. This paper describes the methods and results of the recruitment strategy used to achieve this...
  7. ncbi request reprint Gaps in primary care documentation of cardiovascular risk factors
    Natasha Rafter
    Clinical Trials Research Unit, University of Auckland, Auckland, New Zealand
    N Z Med J 121:24-33. 2008
    ..This requires knowledge of a person's age, sex, ethnicity, medical and family history, blood pressure, total and HDL cholesterol, diabetes, and smoking status...
  8. doi request reprint Polypill-based therapy likely to reduce ethnic inequities in use of cardiovascular preventive medications: Findings from a pragmatic randomised controlled trial
    Vanessa Selak
    Department of Epidemiology and Biostatistics, University of Auckland, New Zealand
    Eur J Prev Cardiol 23:1537-45. 2016
    ....
  9. pmc The efficacy and tolerability of 'polypills': meta-analysis of randomised controlled trials
    C Raina Elley
    School of Population Health, University of Auckland, Auckland, New Zealand
    PLoS ONE 7:e52145. 2012
    ..To assess the blood pressure and lipid-lowering efficacy and tolerability of 'polypills' used in cardiovascular disease prevention trials...
  10. ncbi request reprint Cardiovascular risk management of different ethnic groups with type 2 diabetes in primary care in New Zealand
    C Raina Elley
    Department of General Practice and Primary Health Care, University of Auckland, Auckland, New Zealand
    Diabetes Res Clin Pract 79:468-73. 2008
    ..To examine cardiovascular preventive and renal protective treatment for different ethnic groups with diabetes in primary care...
  11. doi request reprint Do polypills lead to neglect of lifestyle risk factors? Findings from an individual participant data meta-analysis among 3140 patients at high risk of cardiovascular disease
    Vanessa Selak
    Department of Epidemiology and Biostatistics, University of Auckland, New Zealand
    Eur J Prev Cardiol 23:1393-400. 2016
    ....
  12. ncbi request reprint Dispensing data captures individual-level use of aspirin for cardiovascular disease prevention, despite availability over-the-counter
    Vanessa Selak
    Department of Epidemiology and Biostatistics, University of Auckland, Private Bag 92019, Auckland Mail Centre, Auckland 1142, New Zealand
    N Z Med J 129:21-8. 2016
    ..To assess the level of agreement in aspirin use measured by self-report and dispensing data...
  13. ncbi request reprint Will a web-based cardiovascular disease (CVD) risk assessment programme increase the assessment of CVD risk factors for Maori?
    Robyn Whittaker
    Health Gain Team, Waitemata District Health Board, Takapuna, Auckland
    N Z Med J 119:U2077. 2006
    ..National guidelines on the clinical management of CVD risk recommend a comprehensive risk assessment be completed as a prerequisite for identifying patients most likely to benefit from treatment...